Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLEGRA vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Seasonal allergic rhinitis,Chronic idiopathic urticaria
Mild to moderate pain,Fever
60 mg orally twice daily or 180 mg orally once daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is approximately 14.4 hours in healthy adults, allowing for twice-daily dosing. In patients with renal impairment, half-life may be prolonged (up to 59 hours in severe impairment).
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Minimally metabolized; undergoes hepatic metabolism via CYP3A4 to a lesser extent; mainly excreted unchanged in feces and urine.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for the majority of fecal elimination. Renal elimination is minimal due to extensive tubular reabsorption.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
60-70% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Vd is 5.4-6.7 L/kg, indicating extensive extravascular distribution. This large Vd reflects wide tissue penetration, though fexofenadine does not cross the blood-brain barrier significantly.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability is approximately 33% (range 20-50%), with food reducing absorption by up to 20%. The absolute bioavailability is low due to first-pass metabolism and efflux transport (P-glycoprotein).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For GFR < 30 m L/min: 60 mg orally once daily.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No adjustment required for hepatic impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Children 6-11 years: 30 mg orally twice daily; Children ≥12 years: same as adult.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific adjustment; use with caution due to potential renal impairment.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Renal impairment: reduce dose in patients with Cr Cl < 80 m L/min; avoid use with known hypersensitivity; caution in patients with hepatic impairment.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to fexofenadine or any component of the formulation; severe renal impairment (Cr Cl < 30 m L/min) for the tablet formulation.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Fruit juices (apple, orange, grapefruit) reduce fexofenadine absorption by up to 36%, 36%, and 20% respectively; avoid concomitant intake within 4 hours; food does not significantly affect absorption, but administration with high-fat meal may slightly delay absorption; no specific food restrictions beyond fruit juice timing.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Fexofenadine (ALLEGRA) is classified as FDA Pregnancy Category C. Animal studies in rats and rabbits at doses up to 3 and 7 times the maximum recommended human dose (MRHD) respectively showed no evidence of teratogenicity. However, there are no adequate and well-controlled studies in pregnant women. First trimester: Limited human data; theoretical risk based on lack of data. Second and third trimesters: No known specific fetal risks; antihistamines in late pregnancy may cause uterine irritability and neonatal withdrawal symptoms (tremors, irritability) if used near term. Overall, risk is considered low but not zero.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Fexofenadine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 1.0. Based on a study, an exclusively breastfed infant would receive a dose of about 0.45% of the maternal weight-adjusted dose, which is considered negligible. No adverse effects have been reported in breastfed infants. The American Academy of Pediatrics considers fexofenadine compatible with breastfeeding. However, caution is advised for premature infants or those with renal impairment.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No specific dose adjustments are recommended during pregnancy due to minimal changes in pharmacokinetics. However, pregnancy can increase volume of distribution and renal blood flow, but studies show that fexofenadine exposure (AUC) is similar between pregnant and non-pregnant women. Dosing remains 60 mg twice daily or 180 mg once daily for seasonal allergies. For patients with renal impairment (creatinine clearance <80 m L/min), reduce starting dose to 60 mg once daily regardless of pregnancy status.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
ALLEGRA (fexofenadine) is a non-sedating antihistamine; avoid co-administration with fruit juices (apple, orange, grapefruit) as they reduce absorption; onset within 1 hour, duration 12-24 hours; dose adjustment needed in renal impairment (Cr Cl <80 m L/min): start 60 mg once daily; not significantly metabolized by CYP450, low drug interaction potential; acts as a P-glycoprotein substrate.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take on an empty stomach with water for best absorption.,Do not take with fruit juices (apple, orange, grapefruit) as they decrease effectiveness.,May cause drowsiness in rare cases; avoid driving if affected.,Use consistently for best symptom control; do not exceed recommended dose.,If you have kidney disease, consult your doctor before use.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLEGRA vs ACEPHEN, answered by our medical review team.
ALLEGRA is a Antihistamine (Nonsedating) that works by Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLEGRA and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLEGRA is: 60 mg orally twice daily or 180 mg orally once daily.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLEGRA and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLEGRA is classified as Category C. Fexofenadine (ALLEGRA) is classified as FDA Pregnancy Category C. Animal studies in rats and rabbits at doses up to 3 and 7 times the maximum recommended human dose (MRHD) respecti. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.